Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma

被引：4

作者：

Kahl, Christoph ^{[1
]}

Hilgendorf, Inken

Freund, Mathias

Casper, Jochen ^{[2
]}

机构：

[1] Univ Rostock, Klin & Poliklin Innere Med, Hamatol Onkol Abt, Dept Internal Med,Div Hematol & Oncol, D-18057 Rostock, Germany

[2] Klinikum Oldenburg, Dept Hematol & Oncol, Oldenburg, Germany

来源：

ONKOLOGIE | 2008年 / 31卷 / 8-9期

关键词：

D O I：

10.1159/000142359

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：485 / 485

页数：1

共 3 条

[1] Continuous daily dosing (CDD) study of sunitinib malate (SU) in patients (pts) with advanced GIST compares favorably with intermittent dosing [J].

Blay, J. Y. ;

George, S. ;

Casali, P. G. ;

Le Cesne, A. ;

Morgan, J. A. ;

Pokela, J. ;

Quigley, M. T. ;

Tasse, V. ;

Baum, C. M. ;

Demetri, G. D. .

EJC SUPPLEMENTS, 2007, 5 (04) :402-402

[2]

Mendel DB, 2003, CLIN CANCER RES, V9, P327

[3] Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

Tomczak, Piotr ;

Michaelson, M. Dror ;

Bukowski, Ronald M. ;

Rixe, Olivier ;

Oudard, Stephane ;

Negrier, Sylvie ;

Szczylik, Cezary ;

Kim, Sindy T. ;

Chen, Isan ;

Bycott, Paul W. ;

Baum, Charles M. ;

Figlin, Robert A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :115-124

← 1 →